Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 13.51% and Operating profit at -66.06% over the last 5 years
2
The company has declared negative results for the last 7 consecutive quarters
3
With ROE of -0.01%, it has a fair valuation with a 1.39 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,877 Million (Small Cap)
NA (Loss Making)
NA
0.30%
0.25
-0.01%
1.39
Revenue and Profits:
Net Sales:
613 Million
(Quarterly Results - Jun 2025)
Net Profit:
2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.39%
0%
-9.39%
6 Months
0.18%
0%
0.18%
1 Year
-4.86%
0%
-4.86%
2 Years
-43.38%
0%
-43.38%
3 Years
-67.38%
0%
-67.38%
4 Years
-80.72%
0%
-80.72%
5 Years
-59.73%
0%
-59.73%
Shanghai Titan Scientific Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.51%
EBIT Growth (5y)
-66.06%
EBIT to Interest (avg)
43.90
Debt to EBITDA (avg)
1.80
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
0.69
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
89.29%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
23.51%
ROE (avg)
3.93%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.39
EV to EBIT
364.11
EV to EBITDA
39.73
EV to Capital Employed
1.31
EV to Sales
1.70
PEG Ratio
NA
Dividend Yield
0.30%
ROCE (Latest)
0.36%
ROE (Latest)
-0.01%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
612.80
600.20
2.10%
Operating Profit (PBDIT) excl Other Income
23.20
34.20
-32.16%
Interest
10.60
10.20
3.92%
Exceptional Items
7.70
0.00
Consolidate Net Profit
2.40
1.90
26.32%
Operating Profit Margin (Excl OI)
-3.10%
15.00%
-1.81%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 2.10% vs -20.46% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 26.32% vs 137.50% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,871.50
2,761.30
3.99%
Operating Profit (PBDIT) excl Other Income
130.30
149.00
-12.55%
Interest
44.70
31.80
40.57%
Exceptional Items
1.80
12.30
-85.37%
Consolidate Net Profit
7.80
75.30
-89.64%
Operating Profit Margin (Excl OI)
10.60%
28.70%
-1.81%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 3.99% vs 6.15% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -89.64% vs -42.82% in Dec 2023
About Shanghai Titan Scientific Co., Ltd. 
Shanghai Titan Scientific Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






